Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Vehicle Recompete: NA — Idc 75D30122D13176

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This contract pertains to vehicle ordering under the identifier 75D30122D13176, with an ordering period that concludes on July 4, 2027. Currently, there are no active task orders associated with the contract. The contract has an IDV ceiling of $2,406,608, and it is managed by the CDC Office of Acquisition Services under the Department of Health and Human Services. It is classified as a likely recompete opportunity with a medium confidence level of 45%. One notable task order under this contract is for the Maryland Department of Health, valued at $406,608. The original solicitation number is 75D301-22-Q-74375. The contract does not involve any set-aside provisions, and it falls under the NAICS code 923120. The forecast for this vehicle recompete was posted on January 4, 2026. Additional details such as specific locations and points of contact have not been provided.

General Info

Vehicle order contract 75D30122D13176, $2.4M ceiling, ends July 2027, medium recompete chance.

Agency

Department Of Health And Human Services → CDC Office Of Acquisition ServicesView Agency

NAICS

923120 - Administration of Public Health ProgramsView NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

pre-forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → CDC Office Of Acquisition Services
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Health And Human Services → CDC Office Of Acquisition Services
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
NA (Idc) — vehicle 75D30122D13176 ordering period ends 2027-07-04T00:00:00.000Z. 0 active task orders valued at $0.
Vscp maryland Original Solicitation: 75D301-22-Q-74375 IDV Ceiling: $2,406,608 Set-Aside: No set aside used. Contracting Office: CDC Office Of Acquisition Services Agencies: Department of Health and Human Services Classification: recompete-likely (Confidence: medium - 45/100)
Top task orders by value: - VSCP MARYLAND ($406,608) - MARYLAND DEPARTMENT OF HEALTH

Similar Contracts

Same NAICS industry code

NAICS: 923120
New
Federal
Electronic Case Reporting
Solicitation # 75D30126Q79169ElectronicCaseReporting
The Centers for Disease Control and Prevention (CDC), through the National Institute for Occupational Safety and Health (NIOSH), is soliciting proposals for a Firm Fixed Price contract to provide professional public health informatics and epidemiological support. The objective is to implement, expand, and evaluate electronic case reporting (eCR) for priority occupational respiratory diseases, specifically silicosis, asbestosis, work-related asthma, and malignant mesothelioma. The selected jurisdictional public health department will be responsible for establishing eCR connectivity to AIMS and RCKMS platforms, developing clinical logic sets, validating trigger performance, and creating standardized workflows for occupation and industry data. Key deliverables include a project plan, IRB/PRA documentation, interim and final reports, and knowledge dissemination materials such as webinars and digital resources. The period of performance is a 12-month term from September 1, 2026, through August 31, 2027, with work performed at the contractor's facilities in Atlanta, Georgia. Proposals must be submitted in two separate volumes—Technical and Price—by August 25, 2026. The technical proposal is limited to 25 pages and will be evaluated based on the technical approach, staffing plan, and management plan. Award will be based on a best value trade-off, requiring the proposal to be technically acceptable and offer a fair and reasonable price. Contractors must adhere to strict compliance standards, including Section 508 accessibility for all ICT deliverables, HIPAA regulations for protected health information, and mandatory non-disclosure agreements for all personnel.
CDC Office Of Acquisition Services

POSTED

4 days ago

DEADLINE

in 1 day
View Details
NAICS: 923120
New
Grant
Advancing Global Health
Solicitation # DFOP0017890
The Department of State, through the Bureau of Global Health Security and Diplomacy, has issued Annual Program Statement DFOP0017890 to advance the America First Global Health Strategy. This supplemental framework seeks projects that save lives, strengthen health systems, and enhance efficiency to ensure U.S. investments benefit American safety and prosperity. The program focuses on several key areas, including child protection and development for ages 0 to 17, global health security through rapid outbreak detection and containment, and the advancement of integrated health systems, specifically within the Philippines. Total estimated funding is up to 4.5 billion dollars, with the potential for up to 100 awards ranging from a minimum of 500,000 dollars to a maximum of 250 million dollars. Applicants must submit a Statement of Interest (SOI) via grants.gov or MyGrants, adhering to a strict five-page narrative limit and specific formatting requirements. Evaluation is based on a multi-step process including technical eligibility and risk reviews, with equal weighting placed on the quality of the program idea and the organization's capacity and previous grant record. Proposed projects must be completed within one to five years. Key compliance requirements include maintaining an active SAM.gov registration and UEI for phase two proposals, adhering to 2 CFR 200 cost principles, and providing certifications regarding anti-discrimination laws and trafficking in persons for awards exceeding 500,000 dollars performed outside the United States.
Bureau Of Global Health Security And Diplomacy

POSTED

6 days ago

DEADLINE

in 6 months
View Details
NAICS: 923120
Grant
Ending HIV and TB as public health threats through an accelerated and sustained comprehensive response in India
Solicitation # CDC-RFA-JG-26-0142
Solicitation CDC-RFA-JG-26-0142 is a cooperative agreement issued by the Centers for Disease Control and Prevention (CDC) to support India's Ministry of Health and Family Welfare, specifically the National AIDS Control Organization and the Central Tuberculosis Division. The program aims to eradicate HIV and TB as public health threats by enhancing epidemic control systems, improving case detection, and transitioning essential services to local ownership. Key objectives include closing gaps in testing and treatment, promoting viral suppression, and integrating services for HIV and co-morbidities. The project is designed for a five-year period of performance, with an anticipated funding amount of 6,000,000 dollars for the first year, subject to the availability of funds. Applicants must be registered in SAM.gov with a valid Unique Entity Identifier and submit their proposals via Grants.gov by September 16, 2026. Local organizations in India are required to provide proof of Foreign Contribution Regulation Act registration to be considered responsive. Evaluation is based on a merit review process, with a significant focus on data monitoring and evaluation plans and adaptive management systems. Preference is given to local organizations, who may receive a 30-point advantage in scoring. The award process follows a trade-off basis, weighing technical merit, alignment with CDC priorities, and risk reviews rather than relying solely on the lowest cost.
Centers For Disease Control-Ghc

POSTED

7 days ago

DEADLINE

in 23 days
View Details
NAICS: 923120
SLED
Enhancement and Expansion of ED-MOUD and Overdose Education and Naloxone Distribution Programs with Outcomes Analysis
Solicitation # 2026-RFA-203
The Mississippi State Department of Health, under the CDC Overdose Data to Action in States Cooperative Agreement, is seeking a subgrantee to enhance and expand Emergency Department-based Medication for Opioid Use Disorder and Overdose Education and Naloxone Distribution programs. This initiative aims to reduce opioid-related morbidity and mortality by improving clinical workflows, expanding access to evidence-based treatment initiation, and strengthening referral pathways and warm-handoff processes to specialty psychiatry and behavioral health services. The project emphasizes the integration of overdose prevention and patient navigation to ensure continuity of care following emergency department encounters. A critical component of the contract is an outcomes-focused analysis to evaluate program effectiveness, patient engagement, and naloxone utilization. This data-driven approach will identify implementation challenges and strategies for sustainability and expansion. The project requires strict adherence to CDC reporting timelines for morbidity and mortality surveillance, including the submission of data via the DOSE and SUDORS systems through May 2028. This solicitation, numbered 2026-RFA-203, was posted on August 14, 2026, with a response deadline of August 28, 2026, and will be performed within the state of Mississippi.
Pharmacy

POSTED

10 days ago

DEADLINE

in 4 days
View Details

More opportunities from Department Of Health And Human Services → CDC Office Of Acquisition Services

Same awarding agency

NAICS: 541715
SBIR / STTR
NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
Solicitation # PA-27-102
This solicitation supports Small Business Technology Transfer (STTR) grants through the National Institutes of Health to fund research and development projects that advance innovative technologies with potential for commercialization, requiring a formal collaboration between a U.S.-owned small business and a nonprofit research institution. The award is made solely to the small business, regardless of where the principal investigator is employed, and projects must align with the missions of NIH, CDC, or FDA components. Funding is available for Phase I, Phase II, Direct to Phase II, and Fast-Track applications, with Fast-Track allowing combined Phase I and II review to streamline the process. Direct to Phase II is an option for businesses that have already demonstrated technical merit without prior Phase I funding, provided the application is submitted as a new proposal, not a renewal. Only one Phase II award is permitted per Phase I project, and Phase IIB Strategic Breakthrough applications must go through a separate solicitation. Applications must focus on feasibility or R&D that supports public health goals and are subject to restrictions on clinical trials, which are not permitted under this NOFO if exclusively aligned with specific NIH institutes including NIAID, NIAMS, NIDCR, NIDDK, NIMHD, NCATS, and ORIP. The funding opportunity is part of the broader SBIR/STTR mandate, which requires NIH to set aside 0.45% of its extramural budget for STTR, ensuring support for small businesses with fewer than 500 employees. Applicants are encouraged to consult with program staff prior to submission to ensure alignment with funding priorities and to use the Assignment Request Form to suggest an appropriate awarding component, though such identification is not mandatory. The solicitation closes on August 5, 2026, and information on program details, priorities, and frequently asked questions is available through the NIH Seed Fund portal and related government strategies including the Make Our Children Healthy Again initiative.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
SBIR / STTR
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
Solicitation # PA-27-100
This funding opportunity supports U.S. small businesses in advancing early-stage research and development toward commercialization through the SBIR program, administered by the National Institutes of Health, Centers for Disease Control and Prevention, and Food and Drug Administration. Eligible small businesses must be U.S.-owned and operated with fewer than 500 employees and are expected to lead the majority of the technical effort, with the principal investigator primarily employed by the business. The program offers Phase I grants to establish technical feasibility, Phase II grants to advance development toward market readiness, and two special pathways: Direct to Phase II for projects with prior proof of concept but no prior Phase I award, and Fast-Track for combined Phase I and Phase II submissions reviewed concurrently to accelerate progress. All awards are granted to the small business, and commercialization must be pursued using non-SBIR funds after Phase II. The scientific scope must align with the missions of participating NIH, CDC, or FDA components, focusing on health improvement and public health innovation, with applicants encouraged to consult specific institute priorities and the White House’s Make Our Children Healthy Again Strategy. While clinical trials are permitted, they are explicitly excluded if the application aligns solely with certain NIH institutes or all FDA centers, making alignment critical for responsiveness. Applications must be submitted through the designated portal by the deadline, and while applicants are not required to specify an awarding component during submission, consultation with program staff beforehand is strongly advised to ensure proper alignment. The solicitation operates under a complete small business set-aside mandate and is open to new applications only, with no renewals accepted for Direct to Phase II submissions.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
SBIR / STTR
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
Solicitation # PAR-27-098
The Commercialization Readiness Pilot (CRP) program, issued under PAR-27-098, provides late-stage research and development funding and technical assistance to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award or a Phase IIB Strategic Breakthrough award. This initiative is designed to bridge the gap between Phase II completion and full commercialization by supporting activities that require significant outsourcing, such as regulatory strategy, intellectual property development, manufacturing optimization, pre-clinical product development, and clinical trials—though not all NIH institutes accept clinical trial proposals. The program permits substantial outsourcing to contract research organizations but requires the small business to maintain active oversight and management of all scientific, financial, and administrative aspects of the work, with justified budget allocations reflecting this role. CRP funding cannot cover FDA filing fees or include separate Technical and Business Assistance (TABA) funds. Eligible applicants must be small business concerns under 500 employees meeting SBA size standards, and proposals must align with the mission of participating NIH components. The solicitation explicitly excludes applications that propose clinical trials solely aligned with certain NIH institutes, including NHLBI, NIAID, NIDDK, and others listed, which do not accept such trials under this program. Applications are limited to Type 1 new submissions, and prior Phase II funding is mandatory for eligibility. Applicants are strongly encouraged to consult with NIH program staff before submitting to ensure alignment with the most appropriate funding mechanism, as the Phase IIB Strategic Breakthrough program (PA-27-101) may be better suited for some projects with matching fund requirements. The solicitation is active through August 5, 2026, under a total small business set-aside, and further details are available through the NIH SBIR/STTR portal.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

3 months ago

DEADLINE

in 7 months
View Details
NAICS: 541715
Federal
Vehicle Recompete: Idc 75N95022D00017This contract is an indefinite delivery contract vehicle (IDC) with the identifier 75N95022D00017, overseeing the ordering period from September 5, 2022, through September 4, 2027. It supports the National Institute on Drug Abuse (NIDA) data, statistics, and clinical trial operations under the Department of Health and Human Services, managed by the National Institutes of Health (NIH). The contract has a ceiling value of approximately $44.3 million and does not involve any set-aside provisions. It represents a full recompete classification, indicating a competitive solicitation process to award the contract. Currently, there are no active task orders valued at zero, but several significant task orders have been executed under this vehicle. Several key task orders highlight the contract’s scope and value, all awarded to The Emmes Company, LLC. These task orders cover a variety of research and analytical services, including the management and support of the Data and Statistics Center (DSC) from March 2025 to February 2026 ($1.85 million), data analysis related to GLP-1 as an adjunct to buprenorphine from May 2025 to February 2028 ($1.4 million), and various other clinical and secondary analysis projects concerning opioid use disorder and related research, with task order values ranging from approximately $375,000 to $800,000. The work performed under these task orders reflects a comprehensive support framework for clinical trials and data management activities essential to advancing research efforts around drug abuse and treatment strategies.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

6 months ago

DEADLINE

N/A
View Details